AKTX vs. COCP, ONCT, ORMP, ACET, IMUX, AMLX, ANL, OPTN, ANVS, and NVCT
Should you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Cocrystal Pharma (COCP), Oncternal Therapeutics (ONCT), Oramed Pharmaceuticals (ORMP), Adicet Bio (ACET), Immunic (IMUX), Amylyx Pharmaceuticals (AMLX), Adlai Nortye (ANL), OptiNose (OPTN), Annovis Bio (ANVS), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical preparations" industry.
Akari Therapeutics (NASDAQ:AKTX) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.
5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 38.9% of Akari Therapeutics shares are held by company insiders. Comparatively, 25.6% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Akari Therapeutics had 3 more articles in the media than Cocrystal Pharma. MarketBeat recorded 5 mentions for Akari Therapeutics and 2 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.81 beat Akari Therapeutics' score of 0.15 indicating that Cocrystal Pharma is being referred to more favorably in the news media.
Akari Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.
Akari Therapeutics received 240 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 75.86% of users gave Cocrystal Pharma an outperform vote while only 53.69% of users gave Akari Therapeutics an outperform vote.
Akari Therapeutics' return on equity of 0.00% beat Cocrystal Pharma's return on equity.
Cocrystal Pharma has a consensus target price of $10.00, suggesting a potential upside of 354.55%. Given Cocrystal Pharma's higher probable upside, analysts clearly believe Cocrystal Pharma is more favorable than Akari Therapeutics.
Summary
Akari Therapeutics and Cocrystal Pharma tied by winning 6 of the 12 factors compared between the two stocks.
Get Akari Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akari Therapeutics Competitors List
Related Companies and Tools
